On November 24th, Takeda Pharmaceuticals announced that a new indication for its innovative digestive product, Fumarate Vonorasone Tablets, has been approved by the National Medical Products Administration (NMPA) of China for use in combination with appropriate antibiotics to eradicate Helicobacter pylori.
It is reported that the quadruple regimen based on fumarate vorolazone tablets is currently the first approved quadruple regimen in China to eradicate Helicobacter pylori containing bismuth. Research data shows that the eradication rate of Helicobacter pylori using a new protocol based on fumarate vorolazone is as high as 94.1%, ranking first in the eradication rate of Helicobacter pylori among the Chinese population.
Public information shows that Helicobacter pylori is a pathogenic bacterium associated with various major chronic diseases, which is infectious and can cause various gastrointestinal and extraintestinal diseases, including chronic gastritis, peptic ulcer, gastric mucosa associated lymphoid tissue lymphoma, and so on. The infection rate of Helicobacter pylori among residents in China is about 46.7%, and the infection rate of Helicobacter pylori in households is as high as 71.2%.
Takeda Pharmaceuticals stated that digestion, as one of its four core therapeutic areas in the Chinese market, has entered a new stage of development; In the future, enterprises will continue to focus on the health needs of the Chinese public and deeply explore the field of digestion. It is reported that the new indication for the combination of fumarate and antibiotics to eradicate Helicobacter pylori has been approved in 15 countries and regions around the world, including Japan and the United States.